ERBB2 and cancer: According to recent randomized control trials (RCTs), escalated treatments such as capecitabine, atezolizumab, sacituzumab, and pembrolizumab for non-pCR triple negative breast cancer (TNBC) and trastuzumab emtansine (T-DM1) for non-pCR HER2 + cancer after NAC led to successful improvement in the oncologic outcomes (11–15).